RU2018119120A - D-пролиновые производные в качестве агента, уменьшающего количество sap - Google Patents
D-пролиновые производные в качестве агента, уменьшающего количество sap Download PDFInfo
- Publication number
- RU2018119120A RU2018119120A RU2018119120A RU2018119120A RU2018119120A RU 2018119120 A RU2018119120 A RU 2018119120A RU 2018119120 A RU2018119120 A RU 2018119120A RU 2018119120 A RU2018119120 A RU 2018119120A RU 2018119120 A RU2018119120 A RU 2018119120A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pharmaceutical composition
- sap
- composition according
- amount
- Prior art date
Links
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical class OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 206010002022 amyloidosis Diseases 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1518950.9A GB201518950D0 (en) | 2015-10-27 | 2015-10-27 | Compound |
| GB1518950.9 | 2015-10-27 | ||
| PCT/EP2016/075632 WO2017072099A1 (en) | 2015-10-27 | 2016-10-25 | D-proline derivatives as sap depleting agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018119120A true RU2018119120A (ru) | 2019-11-28 |
Family
ID=55130261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018119120A RU2018119120A (ru) | 2015-10-27 | 2016-10-25 | D-пролиновые производные в качестве агента, уменьшающего количество sap |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10328052B2 (enExample) |
| EP (1) | EP3368532B1 (enExample) |
| JP (2) | JP6789288B2 (enExample) |
| KR (1) | KR20180067559A (enExample) |
| CN (1) | CN108368095B (enExample) |
| AU (1) | AU2016345462A1 (enExample) |
| BR (1) | BR112018008582A2 (enExample) |
| CA (1) | CA3002710A1 (enExample) |
| ES (1) | ES2781550T3 (enExample) |
| GB (1) | GB201518950D0 (enExample) |
| RU (1) | RU2018119120A (enExample) |
| WO (1) | WO2017072099A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202111866D0 (en) | 2021-08-18 | 2021-09-29 | Ucl Business Plc | Prodrugs for use in the treatment of tissue damage |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859031A (en) * | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| PT915088E (pt) * | 1997-10-31 | 2003-01-31 | Hoffmann La Roche | Derivados de d-prolina |
| US6903129B2 (en) * | 2001-12-14 | 2005-06-07 | Hoffman-La Roche Inc. | D-proline prodrugs |
| US7265140B2 (en) | 2003-09-23 | 2007-09-04 | Pfizer Inc | Acyloxymethylcarbamate prodrugs of oxazolidinones |
| US8236792B2 (en) * | 2008-05-23 | 2012-08-07 | Janssen Pharmaceutica Nv | Substituted pyrrolidine amides as modulators of the histamine H3 receptor |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201407506D0 (en) * | 2014-04-29 | 2014-06-11 | Glaxosmithkline Ip Dev Ltd | Novel compound |
-
2015
- 2015-10-27 GB GBGB1518950.9A patent/GB201518950D0/en not_active Ceased
-
2016
- 2016-10-25 CA CA3002710A patent/CA3002710A1/en not_active Abandoned
- 2016-10-25 KR KR1020187011871A patent/KR20180067559A/ko not_active Withdrawn
- 2016-10-25 EP EP16823162.9A patent/EP3368532B1/en active Active
- 2016-10-25 BR BR112018008582A patent/BR112018008582A2/pt not_active Application Discontinuation
- 2016-10-25 US US15/771,442 patent/US10328052B2/en active Active
- 2016-10-25 JP JP2018521655A patent/JP6789288B2/ja not_active Expired - Fee Related
- 2016-10-25 CN CN201680073108.0A patent/CN108368095B/zh not_active Expired - Fee Related
- 2016-10-25 RU RU2018119120A patent/RU2018119120A/ru not_active Application Discontinuation
- 2016-10-25 AU AU2016345462A patent/AU2016345462A1/en not_active Abandoned
- 2016-10-25 ES ES16823162T patent/ES2781550T3/es active Active
- 2016-10-25 WO PCT/EP2016/075632 patent/WO2017072099A1/en not_active Ceased
-
2020
- 2020-10-30 JP JP2020182835A patent/JP7053762B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3368532A1 (en) | 2018-09-05 |
| JP6789288B2 (ja) | 2020-11-25 |
| JP2018531967A (ja) | 2018-11-01 |
| JP2021035963A (ja) | 2021-03-04 |
| KR20180067559A (ko) | 2018-06-20 |
| EP3368532B1 (en) | 2020-01-15 |
| BR112018008582A2 (pt) | 2018-10-30 |
| AU2016345462A1 (en) | 2018-04-26 |
| ES2781550T3 (es) | 2020-09-03 |
| GB201518950D0 (en) | 2015-12-09 |
| CN108368095A (zh) | 2018-08-03 |
| CN108368095B (zh) | 2021-06-08 |
| US10328052B2 (en) | 2019-06-25 |
| CA3002710A1 (en) | 2017-05-04 |
| US20190060274A1 (en) | 2019-02-28 |
| JP7053762B2 (ja) | 2022-04-12 |
| WO2017072099A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| RU2017105353A (ru) | Соединения | |
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2016510326A5 (enExample) | ||
| JP2020534270A5 (enExample) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| MX2020012377A (es) | Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades. | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| EP4410295A3 (en) | Use of vibegron to treat overactive bladder | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| RU2018130097A (ru) | Лечение экземы кистей | |
| RU2017126153A (ru) | Фармацевтическая комбинация | |
| JP2017514829A5 (enExample) | ||
| RU2018119120A (ru) | D-пролиновые производные в качестве агента, уменьшающего количество sap | |
| RU2019102757A (ru) | Производные этинила | |
| JP2015512948A5 (enExample) | ||
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| JP2017530142A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20191028 |